Neuropsychiatric symptoms associated with efavirenz: Prevalence, correlates and management. A neurobehavioral review

AIDS Reviews

Volumn 11, Issue 2, 2009, Pages 103-109

  Muñoz Moreno, José A ^a,b   Fumaz, Carmina R ^a,b   Ferrer, Maria J ^a,b   González Garcia, Marian ^a,b   Moltó, José ^a,b   Negredo, Eugènia ^a,b   Clotet, Bonaventura ^a,b,c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c IrsiCaixa Foundation   (Spain)

Author keywords

Antiretroviral therapy; Efavirenz; HIV infection

Indexed keywords

EFAVIRENZ; PROTEINASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABNORMAL DREAMING; ANXIETY; ASTHENIA; CENTRAL NERVOUS SYSTEM DISEASE; CIRCUMORAL PARESTHESIA; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; COMPULSIVE PERSONALITY DISORDER; CONFUSION; DEPRESSION; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EMOTIONAL DISORDER; ERECTILE DYSFUNCTION; EUPHORIA; FATIGUE; GASTROINTESTINAL DISEASE; GENETIC PREDISPOSITION; HALLUCINATION; HUMAN; INSOMNIA; IRRITABILITY; LEARNING DISORDER; LIBIDO DISORDER; LONG TERM CARE; MEMORY DISORDER; MENTAL DISEASE; MOOD DISORDER; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; NEUROLOGIC DISEASE; NEUROTOXICITY; NIGHTMARE; PATIENT ATTITUDE; PATIENT COMPLIANCE; POLYNEUROPATHY; PREVALENCE; QUALITY OF LIFE; RESTLESSNESS; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STRESS; SYMPTOMATOLOGY; TREATMENT DURATION; WAKEFULNESS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATHOPHYSIOLOGY; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MENTAL DISORDERS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 68049115405     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. European Medicines Agency (EMEA), 1999: EPARs for Authorised Medicinal Products for Human Use. (Accessed February 5, 2009, at http://www.emea.europa.eu/humandocs/Humans/EPAR/sustiva/sustiva.htm).
2. Wynn H, Brundage R, Fletcher C. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs. 2002;16:595-609.
3. Sustiva. Product Information. European Medicines Agency (EMEA). 1999.
4. Hammer S, Eron J, Reiss P, et al. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555-70.
5. Atripla. New Drug Administration. Food and Drug Administration (FDA). 2006.
6. European Medicines Agency (EMEA), 2008: EPARs for Authorised Medicinal Products for Human Use. (Accessed February 5, 2009, at http://www.emea.europa.eu/humandocs/Humans/EPAR/atripla/atripla.htm).
7. Arendt G, de Nocker D, von Giesen H, Nolting T. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf. 2007;6:147-54.
8. Staszewski S, Morales-Ramirez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865-73.
9. Lochet, P, Peyrière H, Lotth A, et al. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 2003;4: 62-6.
10. Molina J, Ferchal F, Rancinan C, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in HIV-infected patients. J Infect Dis. 2000;182:599-602.
11. Adkins J, Nobles S. Efavirenz. Drugs. 1998;56:1055-66.
12. Clifford D, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143:714-21.
13. Marzolini C, Telenti A, Decosterd L, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV- 1 infected patients. AIDS. 2001;15:71-5.
14. Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J Acquir Immune Defic Syndr. 2004;35:492-502.
15. Pérez-Molina J. Safety and tolerance of efavirenz regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials. 2002;3:279-86.
16. Sabbatani S, Fulgaro C, Rosticelli E. [Efficacy of efavirenz in a mixed population of patients. Identification of drop-out causes.] Infez Med. 2002;10:163-8.
17. Spire B, Carrieri P, Garzot M, L'henaff M, Obadia Y. TRT-5 Group. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care. 2004;16:558-64.
18. Hartmann M, Rump A, Brust J, et al. Evaluation of an efavirenz-containing regimen: an open-label, multicenter study. HIV Clin Trials. 2001;2:421-8.
19. Fumaz C, Tuldrà A, Ferrer M, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor- containing regimens. J Acquir Immune Defic Syndr. 2002;29:244-53.
20. Gutiérrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005;41:1648-53.
21. Fumaz C, Muñoz-Moreno J, Moltó J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr. 2005;38:560-5.
22. Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitortreated patients. HIV Clin Trials. 2005;6:187-96.
23. Braithwaite R, Kozal M, Chang C, et al. Adherence, virologic and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS. 2007;21:1579-89.
24. Rihs T, Begley K, Smith D, et al. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med. 2006;7:544-8.
25. Takahashi M, Ibe S, Kudaka Y, et al. No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART. AIDS Res Hum Retroviruses. 2007;23:983-7.
26. Núñez M, Gonzalez de Requena D, Gallego L, et al. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr. 2001;28:399-400.
27. Gallego L, Barreiro P, del Rio R, et al. Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clin Infect Dis. 2004;38:430-2.
28. Gulick R, Ribaudo H, Shikuma C, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-61.
29. Shulman N, Bosch R, Mellors J, et al. Genetic correlates of efavirenz hypersusceptibility. AIDS. 2004;18:1781-5.
30. Haas D, Ribaudo H, Kim R, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-400.
31. Schackman B, Ribaudo H, Krambrink A, et al. Racial differences in virologic failure associated with adherence and quality of life on efavirenzcontaining regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr. 2007;46:547-54.
32. O'Mahony S, Myint A, Steinbusch H, et al. Efavirenz induces depressivelike behavior, increased stress response and changes in the immune response in rats. Neuroimmunomodulation. 2005;12:293-8.
33. Currier J, Spino C, Grimes J, et al. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr. 2000;24:316-24.
34. Journot V, Chene G, De Castro N, et al. ALIZE Study Group. Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099. Clin Infect Dis. 2006;42:1790-9.
35. Thomas R, Machouf N, Adams D, et al. The effect of a psychotherapeutic intervention support on patients treated by efavirenz. 15th International AIDS Conference, Bangkok 2004 [abstract WePeB5883].
36. Tuldrà A, Fumaz C, Ferrer M, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to HAART. J Acquir Immune Defic Syndr. 2000;25:221-8.
37. Haynes R, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008: CD000011.
38. Reynolds N, Testa M, Su M, et al. AIDS Clinical Trials Group 731 and 384 Teams. Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial. J Acquir Immune Defic Syndr. 2008;47:62-8.